# Alkermes (ALKS) — Analyst Forecast

ALKS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alks/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 5 | 1 | 19 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $50.00 | $59.71 | $65.00 | 7 |

Last price $40.10 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 24, 2026 | Goldman Sachs | Maintained | Neutral | $50.00 |
| Sep 22, 2026 | Baird | Maintained | Outperform | $61.00 |
| Sep 22, 2026 | RBC Capital | Maintained | Outperform | $56.00 |
| Sep 21, 2026 | Needham | Maintained | Buy | $62.00 |
| Jul 29, 2026 | Baird | Maintained | Outperform | $58.00 |
| Jul 29, 2026 | JP Morgan | Maintained | Neutral | $61.00 |
| Jul 28, 2026 | Piper Sandler | Maintained | Overweight | $65.00 |
| Jul 20, 2026 | Stifel | Maintained | Buy | $63.00 |
| Jul 13, 2026 | JP Morgan | Maintained | Neutral | $60.00 |
| Jul 13, 2026 | Needham | Maintained | Buy | $62.00 |
| Jul 2, 2026 | Mizuho | Maintained | Outperform | $65.00 |
| Jun 29, 2026 | B of A Securities | Downgraded | Neutral → Underperform | $38.00 |
| Jun 29, 2026 | Wells Fargo | Maintained | Overweight | $65.00 |
| Jun 24, 2026 | Needham | Maintained | Buy | $61.00 |
| Jun 22, 2026 | TD Cowen | Maintained | Buy | $50.00 |
| Jun 18, 2026 | Needham | Maintained | Buy | $54.00 |
| Jun 9, 2026 | RBC Capital | Maintained | Outperform | $56.00 |
| May 13, 2026 | Baird | Maintained | Outperform | $48.00 |
| May 6, 2026 | Needham | Maintained | Buy | $50.00 |
| May 6, 2026 | Wells Fargo | Maintained | Overweight | $44.00 |

## Frequently Asked Questions

### What is the price target for ALKS stock?

The average 12-month analyst price target for Alkermes (ALKS) is $59.71, with a high estimate of $65.00 and a low of $50.00, across 7 analysts.

### Is ALKS a buy, sell, or hold?

Analysts covering Alkermes currently average a Buy rating: 13 buy, 5 hold and 1 sell, from 19 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for ALKS?

The average price target of $59.71 implies 48.91% upside from the last price of $40.10.

### What is the latest analyst rating on ALKS?

On Sep 24, 2026, Goldman Sachs maintained Alkermes at Neutral with a price target of $50.00.

## Similar Stocks

- [MEDP](https://www.lighthorse.io/tickers/medp) — Medpace Holdings, Inc. - Common Stock
- [AMN](https://www.lighthorse.io/tickers/amn) — AMN Healthcare Services Inc
- [OMCL](https://www.lighthorse.io/tickers/omcl) — Omnicell, Inc. - Common Stock
- [ABEO](https://www.lighthorse.io/tickers/abeo) — Abeona Therapeutics Inc. - Common Stock

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).